ZVRA — Zevra Therapeutics, Inc.

Is ZVRA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Zevra Therapeutics, Inc. (ZVRA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.25. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Zevra Therapeutics, Inc. (ZVRA) appears to be a speculative small-cap biotech where valuation and near-term performance will hinge on financing clarity, clinical or partnership milestones, and investor appetite for higher-risk healthcare names. With limited public disclosure in the supplied inputs and a market environment favoring large-cap defensive pharma, expect muted interest absent a clear catalyst. Monitor cash runway, upcoming data or corporate announcements, and any partnership or M&A signals closely.

Key factors

  • Small-cap biotech profile with limited publicly available financial disclosures in the supplied dataset; cash runway and revenue profile are unclear
  • Company is likely driven by binary clinical or partnership milestones — these can produce sharp upside on positive news or steep declines on setbacks
  • Current market tone favors large-cap, defensive pharma flows which can crowd out speculative small-cap biotech interest in the near term
  • Potential strategic optionality from partnerships or acquisition by larger pharma or specialty-service players given active consolidation themes in the sector
  • Low liquidity and limited social/EDGAR signals in the provided data increase idiosyncratic volatility and investor uncertainty

Risks

  • Clinical trial or regulatory setbacks for any development-stage programs (typical binary risk for small biotechs)
  • Dilution risk from equity raises required to fund operations if cash runway is limited
  • Thin trading volume and low liquidity leading to outsized price moves on modest order flow
  • Competitive pressure from larger, well-funded pharma entrants or platform technologies
  • Market rotation toward large-cap defensives and away from small-cap biotech, reducing investor interest and access to capital
  • Macro/policy shifts (monetary tightening or shifts in risk appetite) that reduce appetite for speculative healthcare names

See today's live rating, score and targets

Members see the live hourly rating for ZVRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.